Nõu E
Scand J Respir Dis Suppl. 1979;104:107-30.
Fifty-four bronchial carcinoma patients in clinico-anatomical stages 1-3 of the disease (localized disease) were randomly assigned to groups for radiotherapy, cyclophosphamide and placebo treatment, respectively. The results were assessed by the survival time and the quality of survival. The median survival time was 6.7 months for radiotherapy, 12.4 months for cyclophosphamide and 11.3 months for placebo. The median total sum of vitagram points was 44.5 for radiotherapy, 90.2 for cyclophosphamide and 81.8 for placebo. When calculated per month, the median sum of vitagram points was 6.2 for radiotherapy, 6.6 for cyclophosphamide and 7.0 for placebo. No significant differences were found between the treatment groups with respect to average survival time and and average vitagram point sums.
54例处于临床解剖分期1 - 3期（局限性疾病）的支气管癌患者被随机分别分配到放疗组、环磷酰胺治疗组和安慰剂治疗组。通过生存时间和生存质量对结果进行评估。放疗组的中位生存时间为6.7个月，环磷酰胺组为12.4个月，安慰剂组为11.3个月。放疗组的活力图表积分总和中位数为44.5，环磷酰胺组为90.2，安慰剂组为81.8。按月计算时，放疗组活力图表积分总和中位数为6.2，环磷酰胺组为6.6，安慰剂组为7.0。在平均生存时间和平均活力图表积分总和方面，各治疗组之间未发现显著差异。
